Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists Webcast (2021)
In just the last decade, the FDA has approved several new therapies for the treatment of prostate cancer. It is critical for urologists to understand the sequencing of agents for the treatment of mHSPC because of the overlapping toxicities and the increasing role for treating mHSPC patients. For each new agent, urologists should be able to identify the active agents and their mechanism of action, analyze the breakthrough treatments in the management of advanced and mHSPC, and describe the indications and combinations for treatment with approved agents in the management of mHSPC. In 2020, the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline was released and will provide critical guidance as the management of advanced prostate cancer patients continues to expand.
To increase urologists understanding of how to translate the latest scientific advances and the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline into their clinical practice, the featured 60-minute panel discussion includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of mHSPC. Faculty will highlight the management of patients with advanced prostate cancer and how therapeutic options have been incorporated into evidence-based guidelines.
This educational activity is supported by independent educational grants from:
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Advanced Practice Providers
At the conclusion of the activity, participants will be able to:
- Identify the active agents and their mechanism of action in the management of metastatic hormone sensitive prostate cancer (mHSPC).
- Review the evidence and outcomes on the treatment of mHSPC as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.
- Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice.
- Analyze breakthrough treatments in the management of advanced and mHSPC.
- Describe the indications and combinations for treatment with approved agents in the management of mHSPC.
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists (2021) will be held virtually on Thursday, March 25, 2021 at 7:00 - 8:00 p.m. EST.
- Click on the TAKE COURSE button.
- Click “Start” under "Live Webinar" in the Course Progress pane.
- Click on the link provided to register in advance for this webinar.
- After registering, you will receive a confirmation email containing information about joining the webinar.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: March, 2021
Expiration Date: March, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation